Rafael Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Rafael Holdings, Inc. (the "Company") on December 23, 2024. The report details a specific corporate event regarding the conversion of a convertible promissory note held by the Company.
Key Financial Metrics and Transaction Details
The filing does not provide consolidated revenue, profit, cash flow, or margin data for the Company. The primary financial event reported is:
- Instrument: Convertible Promissory Note issued by Cyclo Therapeutics, Inc. ("Cyclo") on August 21, 2024.
- Original Principal: $3,000,000.
- Amount Converted: $2,500,000 of the outstanding balance.
- Shares Received: 3,968,254 shares of Cyclo common stock.
- Conversion Price: $0.63 per share (based on Cyclo's closing price on December 20, 2024).
- Post-Conversion Ownership: The Company beneficially owns 39.5% of Cyclo's issued and outstanding common stock.
Material Changes
The material change reported is the reduction of the Company's receivable from Cyclo by $2,500,000 and the corresponding increase in equity investment in Cyclo. The filing text does not provide comparative financial data versus prior periods.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the transaction details. No unusual items or contingencies were disclosed in this report.
Key Facts for Investor Verification
- Verify the remaining outstanding balance of the Cyclo Therapeutics note ($500,000) and its terms.
- Confirm the current market value of the 3,968,254 Cyclo shares held by Rafael Holdings.
- Review Cyclo Therapeutics' recent financial health and stock performance given the significant 39.5% ownership stake.
- Check for any subsequent filings regarding the remaining note balance or additional conversions.